Skip to content

Study · Non-randomized trial · n = 11 · 1993

5 results

The effect of nafarelin on human plasma adrenocorticotrophic hormone and cortisol concentrations.

Overton CE, Kennedy SH, Egan DE, Barlow DH

Human reproduction (Oxford, England)1 Oct 1993

PMID8300812 (opens in a new tab)DOI10.1093/oxfordjournals.humrep.a137897 (opens in a new tab)PepBankPUB-08300812
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialMechanism

    In women treated for gynecological conditions, nafarelin did not significantly change total ACTH secretion.

    In plain wordsIn women treated for gynecological conditions, nafarelin did not significantly change total ACTH secretion.

    Peptide
    Nafarelin
    Outcome
    No significant changeTotal ACTH secretion
    Study

    n = 11

    Comparator
    Pretreatment
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    200 micrograms twice daily · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant changes in total secretion of either ACTH or cortisol.
    3 context sentences
    Summary · context
    This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1).
    Summary · context
    Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment.
    Summary · context
    Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced.
  2. 02HumanNon-randomized trialMechanism

    In women treated for gynecological conditions, nafarelin did not significantly change total cortisol secretion.

    In plain wordsIn women treated for gynecological conditions, nafarelin did not significantly change total cortisol secretion.

    Peptide
    Nafarelin
    Outcome
    No significant changeTotal cortisol secretion
    Study

    n = 11

    Comparator
    Pretreatment
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    200 micrograms twice daily · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    There were no statistically significant changes in total secretion of either ACTH or cortisol.
    3 context sentences
    Summary · context
    This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1).
    Summary · context
    Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment.
    Summary · context
    Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced.
  3. 03HumanNon-randomized trialMechanism

    In seven of 11 women, ACTH rose transiently within the normal range 30-60 minutes after first-day nafarelin administration.

    In plain wordsIn seven of 11 women, ACTH rose temporarily within the normal range 30-60 minutes after first-day nafarelin administration.

    Peptide
    Nafarelin
    Outcome
    IncreaseTransient first-day ACTH rise
    Study

    n = 11

    Comparator
    Pretreatment
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    200 micrograms twice daily · intranasalAs given in this study (human).

    Measurements

    Women with transient ACTH rise
    7 women
    of 11 women, 30-60 min after nafarelin administration on the first day of treatment

    Source sentences

    Summary
    There was a transient rise in ACTH 30-60 min after nafarelin administration on the first day of treatment in seven out of 11 women.
    4 context sentences
    Summary · context
    The rise did not exceed the normal range.
    Summary · context
    This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1).
    Summary · context
    Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment.
    Summary · context
    Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced.
  4. 04HumanNon-randomized trialMechanism

    In women treated for gynecological conditions, nafarelin did not affect cortisol concentrations.

    In plain wordsIn women treated for gynecological conditions, nafarelin did not affect cortisol concentrations.

    Peptide
    Nafarelin
    Outcome
    No significant changeCortisol concentrations
    Study

    n = 11

    Comparator
    Pretreatment
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    200 micrograms twice daily · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Cortisol concentrations were unaffected by nafarelin.
    3 context sentences
    Summary · context
    This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1).
    Summary · context
    Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment.
    Summary · context
    Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced.
  5. 05HumanObservational studyMechanism

    Among nafarelin-treated women, seven with ovarian suppression had lower mean ACTH at all time points than four without suppression.

    In plain wordsAmong nafarelin-treated women, ovarian suppression was linked to lower mean ACTH than in women without suppression.

    Peptide
    Nafarelin
    Outcome
    DecreaseACTH by ovarian suppression
    Study

    n = 11

    Comparator
    Women without ovarian suppression
    Outcome group
    Adrenal Function · Endocrine and hormones
    Studied dose
    200 micrograms twice daily · intranasal · 3 monthsAs given in this study (human).

    Source sentences

    Summary
    Seven women with ovarian suppression (oestradiol concentration < 175 pmol/l by day 28) had consistently lower mean ACTH concentrations at all time points than the four remaining women who had oestradiol concentrations 222-880 pmol/l by day 28.
    3 context sentences
    Summary · context
    This study assessed the effects on plasma adrenocorticotrophic hormone (ACTH) and cortisol concentrations of 3 months' treatment with intranasal nafarelin 200 micrograms b.d. in 11 women (aged 26-43 years) for the treatment of endometriosis (n = 9), fibroids (n = 1) and pre-menstrual syndrome (n = 1).
    Summary · context
    Serial blood samples were taken over 5 h, before and after nafarelin administration on the first day of treatment, and after 1 and 3 months' treatment.
    Summary · context
    Control samples were taken before and after intranasal placebo administration on the day before nafarelin was commenced.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.